TG Therapeutics TGTX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 83.1%-0.6pp | 83.7%-1.7pp | 85.3%-1.6pp | 87%-0.5pp | 87.4%-0.9pp | |
| Operating margin | 21.3%+1.3pp | 20%+0.7pp | 19.3%+0.4pp | 18.9%+3.4pp | 15.5%+2.7pp | |
| Net margin | 66%-6.6pp | 72.6%-11.6pp | 84.1%+70.8pp | 13.3%+3.2pp | 10.1%+3.0pp | |
| EBITDA margin | 21.4%+1.3pp | 20%+0.7pp | 19.3%+0.4pp | 18.9%+3.4pp | 15.5%+2.7pp | |
| Returns | ||||||
| Return on equity | 112.6%+9.8pp | 102.8%-9.2pp | 112%+85.3pp | 26.6%+6.9pp | 19.7%+7.5pp | |
| Return on assets | 42.3%-12.2pp | 54.5%-1.0pp | 55.6%+44.6pp | 11%+3.4pp | 7.6%+2.4pp | |
| Return on invested capital | 23.9%+1.8pp | 22%+2.2pp | 19.8%-6.0pp | 25.8%+5.6pp | 20.2%+4.1pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×-0.1× | 0.8×+0.1× | 0.7×-0.2× | 0.8×+0.1× | 0.8×0.0× | |
| Inventory turnover | 1.3×— | —— | 0.7×+0.2× | 0.5×+0.1× | 0.4×— | |
| Liquidity | ||||||
| Current ratio | 5.8×+1.7× | 4.1×+0.3× | 3.8×0.0× | 3.9×-0.2× | 4×-2.2× | |
| Quick ratio | 5.7×+1.7× | 4×+1.1× | 2.9×-0.1× | 3×-0.1× | 3×-3.2× | |
| Cash ratio | 2.4×+1.8× | 0.5×0.0× | 0.5×-0.3× | 0.8×-0.1× | 0.8×-1.2× | |
| Leverage | ||||||
| Debt-to-equity | 1.3×+0.9× | 0.4×0.0× | 0.4×-0.5× | 0.9×-0.2× | 1.1×-0.1× | |
| Debt-to-assets | 0.5×+0.3× | 0.2×0.0× | 0.2×-0.1× | 0.4×0.0× | 0.4×-0.1× | |
| Net debt / EBITDA | 2.1×+0.7× | 1.4×-0.3× | 1.7×+0.3× | 1.5×-0.6× | 2×+0.3× | |
| Interest coverage | 5.4×+0.8× | 4.6×+0.8× | 3.8×+1.0× | 2.7×+0.6× | 2.1×+0.4× | |
| Per Share | ||||||
| Book value per share | $3.64-9.3% | $4.01+6.4% | $3.77+122% | $1.70+16.6% | $1.46+5.1% | |
| Valuation | ||||||
| Market capitalization | $5.3B+12.1% | $4.73B-17.4% | $5.73B-3.2% | $5.92B-4.4% | $6.19B+32.2% | |
| Enterprise value | $5.62B+14.4% | $4.91B-17.0% | $5.91B-2.2% | $6.05B-4.3% | $6.31B+32.7% | |
| Price / earnings | 11.5×+0.9× | 10.6×-2.2× | 12.8×-85.1× | 97.9×-60.2× | 158.2×-42.2× | |
| Price / sales | 7.6×-0.1× | 7.7×-3.1× | 10.8×-2.3× | 13×-3.0× | 16×+1.8× | |
| Price / book | 9.1×+1.8× | 7.3×-2.1× | 9.4×-12.0× | 21.4×-4.7× | 26.1×+5.0× | |
| EV / EBITDA | 37.5×-2.2× | 39.8×-17.7× | 57.5×-12.9× | 70.4×-35.1× | 105.5×-7.8× | |
| EV / sales | 8×+0.1× | 8×-3.2× | 11.1×-2.2× | 13.3×-3.0× | 16.3×+1.9× | |
| Earnings yield | 8.7%-0.7pp | 9.4%+1.6pp | 7.8%+6.8pp | 1%+0.4pp | 0.6%+0.1pp | |
| PEG ratio | 0×0.0× | 0×— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are TG Therapeutics's profit margins?
- TG Therapeutics (TGTX) runs a 83.1% gross margin and a 21.3% operating margin, with a 66.0% net margin.
- Where do TG Therapeutics's ratios come from?
- Every ratio is computed from TG Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
